The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology,
About the solution
The Institut Pasteur’s outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging (cryo-electron microscopy, cryo-electron tomography, etc.), computational biology and artificial intelligence.
Voisin Consulting Life Sciences (VCLS) is a team of around 300 life sciences professionals, committed to delivering innovative therapies to patients. From discovery to patients, their team of HealthTech product specialists offers integrated solutions from development planning, manufacturing, quality and control, nonclinical and clinical testing, clinical trial operations, safety monitoring, registration and commercialization, post-launch.
About the solution
With a partnershipo with HealthTech and a presence in North America, Europe and Southeast Asia, they design global strategies and adapt execution in each market – accounting for local medical practices, regulatory frameworks and reimbursement landscapes. They have been interacting for more than two decades with regulators, payers and key opinion leaders in these markets. The privileged relationships that they have developed facilitate formal and informal dialogue between the industry and health authorities.
Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.
They support their customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).
About the solution
They are a french company specializing in high-value fine chemistry, is well-equipped to support biotech companies in need of GLP and GMP lots for toxicology studies and IND applications. With expertise in GMP synthesis and a focus on assisting customers from early research to later stages, Roowin is a potential partner for biotechs developing new clinical candidates.
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 40 years, covering the drug development process from early screening through regulatory submission.
About the solution
Porsolt provides discovery and preclinical services (safety & efficacy) including in vitro assays, pathophysiological models in multiple species and cell lines, customized procedures, and tailored solutions. They offer to support drug development using high throughput screening, high content analysis, and high content histology platforms, drug formulation analysis, and bioanalytical services.
Their vast expertise covers the following areas: psychiatric and neurological disorders, cardiac and vascular diseases, oncology, pain, inflammation, gastrointestinal disorders, liver diseases, metabolic and eating disorders, respiratory diseases, dermatology, medical devices, and predictive toxicity of compounds.
ERBC group is a leader in discovery and non-clinical studies, offering to healthcare and chemical professionals a comprehensive range of discovery and preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.
About the solution
At ERBC Group, THEY STRATEGIZE your approach to make your drug development a SUCCESS: – Build on most relevant translational models – Select best predictive biomarkers – Choose state-of-the-art technologies.
Oxeltis is a medicinal chemistry services company created in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company has a small-scale custom synthesis business and hit and lead optimization services in various areas, such as antivirals, antibiotics, and anticancer compounds. Oxeltis’ scientific team comprises 21 experienced chemists with recognized expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, iminosugars, modified sugars, oligosaccharides, and PROTACs. Oxeltis services includes also route scouting and up to 50-100g synthesis. Oxeltis works with European, Japanese, and North American start-ups, pharma companies, and research institutions.
About the solution
Oxeltis team is focused on speed of delivery, quality, and confidentiality of the services and collaborations it develops. Oxeltis has completed more than 35 projects with complex and multi-step synthetic chemistry for pharmaceutical and biotechnology companies, including five of the ten largest global pharmaceutical companies. Several drug candidates delivered to its customers are in clinical development.
Inovotion is a breakthrough in vivo platform without animal experimentation-3Rs with multiple value creation applications in Drug Discovery and Personalize Medicine.
Inovotion’s Drug Discovery solution, for anticancer drugs including Immuno-Oncology, deliver faster results, higher sensitivity, strong reliability, and very large cost savings. By eliminating low-value molecules, Inovotion accelerates the drug discovery process and significantly reduces its costs and the animal use. Inovotion has carried out over 650 in vivo studies for over 130 customers in Pharma and Biotech in Europe, USA, and Asia.
Inovotion develops new applications for Personalized Medicine, based on a unique assay to grow tumor avatars derived from patients’ Organoids, Biopsies or Circulating Tumor Cells (CTCs). Inovotion has so far self-financed the development of its multi-function platform though a successful CRO business (over 45% growth in 2023). Inovotion is now seeking a powerful partner to accelerate its development and disseminate throughout the Biopharma industry in USA and Europe.
About the solution
Inovotion’s Drug Discovery solution is tailored for anticancer drugs, including those in Immuno-Oncology. It provides quicker outcomes, enhanced sensitivity, exceptional reliability, and substantial cost reductions compared to traditional models. By weeding out molecules of low potential, Inovotion expedites the drug discovery journey, drastically cutting down on expenses and the need for animal testing.
Their next generation of in vivo efficacy and toxicity tests: #EFFICACY of oncology or immuno-oncology drugs #EARLY TOXICITY assays #TARGET VALIDATION in oncology #MULTI-CANCER SCREENING to (re)position #MECHANISM OF ACTION (angiogenesis, fibrosis, immune cell infiltration, transciptomic, PK,…) INOVOTION has also developed news assay dedicated to the evaluation of biomaterial.
DIVA Expertise offers an integrated service offering combining advice, studies and research and an innovative concept of “Turnkey R&D Project” whose general objective is to provide manufacturers with solutions and optimizations to their budget, deadline and production issues. Thanks to its expertise in adipose tissue, DIVA. Expertise supports manufacturers in identifying new action targets for their products and in developing a new scientific argument to help them differentiate themselves from existing competition.
About the solution
DIVA Expertise is a Contract Research Company (CRO) organized, to date, around five activities:
1) DIVA Conseils & Expertise: Scientific advice and expertise to support manufacturers in the management and coordination of research projects and in the valorization of the results of their research through the writing of scientific publications in international journals. reading committee.
2) DIVA Tests & Studies: carrying out preclinical tests and studies using innovative and scientifically validated human adipocyte models to provide the first scientific evidence of the effectiveness of an active ingredient or a finished product and to characterize its effects biological and its mode of action.
3) DIVA R&D: the company carries out internal research activity to develop study models that are ever closer to living things and adapted to the needs of manufacturers.
4) DIVA Biological Resources: the preparation and provision of biological resources to industrial or academic research teams.
5) DIVA Analyzes: analyzes of adipose tissue taken directly from volunteer or sick subjects participating in clinical research protocols.
ETAP-Lab is a preclinical CRO renowned for its expertise in the fields of dermatology, neurology, cardiology and gastroenterology. It assesses the effectiveness of drug candidates and medical devices.
Founded in 1991, ETAP-Lab has now worked with 150 companies ranging from small biotechs to large pharmaceutical groups, both in France and further afield. Ever since the company’s earliest days, ETAP-Lab models have consistently offered high translational value associated with relevant protocols. Mainly comprised of scientific experts, our team analyses client requirements, offering guidance and advice in the development of a tailor-made solution.
ETAP-Lab studies are conducted to exacting quality standards, ensuring the reproducibility, transparency and traceability of tests while maintaining responsiveness and offering regular dialogue with our project managers.
About the solution
ETAP-Lab can fast-track your pipeline with preclinical excellence having high predictability level through in vitro and in vivo testing and rodent behavioural analysis:
– DERMATOLOGY: Wide portfolio of original inflammatory (psoriasis, atopic dermatitis) and wound-healing in vivo models.
– CARDIOLOGY: In-depth in vivo studies of major cardiovascular diseases like Pulmonary Arterial Hypertension, Ischemia Reperfusion, and Heart failures.
– NEUROLOGY: Original and translational in vivo and in vitro models of Stroke and neurodegenerative diseases like Alzheimer’s and Parkinson’s models.
– GASTROENTEROLOGY: In vivo models of gastrointestinal disorders like irritable bowel syndrome (IBS) and traveler’s diarrhea. Expertise in metabolic disturbances such as diabetes, obesity, and malnutrition.
Iris Pharma is a world-leading Contract Research Organization (CRO), dedicated to preclinical and clinical research in ophthalmology. Since 1989, they have been offering ophthalmologic drug and device development services to pharmaceutical and biotechnology companies worldwide.
Their focus on the eye allows us to be at the forefront of this field and to help our clients to pass their product through the testing and regulatory process in a rapid and cost-effective manner, allowing them to market their drug and device faster.
At Iris Pharma, quality is a state of mind. Their Quality Assurance program is designed to ensure that your studies are performed in compliance with GLP, GCLP and ICH-GCP requirements, guidelines (FDA, OECD, etc) and local regulatory laws.
About the solution
The CRO has expertise in all ophthalmic indications – from the ocular surface to the posterior segment of the eye – and supports customers, newcomers or experts in ophthalmology, ranging from small start-up companies to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.
In addition to a wide portfolio of services such as proof of concept studies in animal models, GLP preclinical studies, clinical trials and post-market studies, bioanalytical testing, cellular and molecular biology assays, Iris Pharma also offer consulting services to help customers determine the best indication and the best route for molecules and products in development.
To support more than 400 customers worldwide, Iris Pharma maintain a GLP-accredited laboratory for preclinical research and bioanalytical testing and conducts high-quality clinical trials in accordance with ICH GCP guidelines.
